All practice questions

160 questions

Question 21Question →

A 45-year-old man is brought to the emergency department after a propane tank explosion at his home. He is awake, alert, and complaining of severe pain. Physical examination reveals deep partial-thickness (second-degree) and full-thickness (third-degree) burns involving his entire posterior trunk and both of his entire upper extremities. There are also superficial (first-degree) burns involving his entire face and neck. The remainder of his body is unaffected. Based on the Rule of Nines, what is the estimated total body surface area (TBSA) percentage that should be used to calculate his initial fluid resuscitation requirements?

Show answer & explanation

Answer: 36

Answer

36
According to the Rule of Nines for adults, the total body surface area (TBSA) is divided into multiples of 9%. The posterior trunk accounts for 18%, and each entire upper extremity accounts for 9%. The calculation for this patient's deep burns is therefore 18% + 9% + 9% = 36%. First-degree burns (superficial burns), such as those on the patient's face and neck, cause erythema and pain but do not lead to clinically significant systemic fluid shifts; therefore, they are always excluded from the TBSA estimate used for fluid resuscitation calculation.

Step-by-Step Solution

1
Identify the extent of clinically significant burns requiring fluid resuscitation.
Deep partial-thickness and full-thickness burns are located on the posterior trunk and both upper extremities.
Only second-degree (partial-thickness) and third-degree (full-thickness) burns are included in the TBSA calculation for burn fluid resuscitation.
2
Calculate the TBSA for the posterior trunk.
The entire posterior trunk accounts for 18% of the TBSA.
According to the adult Rule of Nines, the entire trunk is 36%, with the anterior portion being 18% and the posterior portion being 18%.
3
Calculate the TBSA for both upper extremities.
The two upper extremities account for 18% of the TBSA (9% for the right arm + 9% for the left arm).
According to the adult Rule of Nines, each entire upper extremity represents 9% of the total body surface area.
4
Evaluate the burns on the face and neck.
The face and neck are excluded from the TBSA calculation.
The face and neck only have superficial (first-degree) burns, which are never included in the Parkland formula or general fluid resuscitation TBSA calculations.
5
Sum the relevant percentages to find the final TBSA.
18% + 9% + 9% = 36%.
Adding the clinically significant regions provides the total TBSA to be used in fluid resuscitation formulas.

Key Concept

Rule of Nines and exclusion of first-degree burns in TBSA calculations
Question 22Question →

A 45-year-old woman is brought to the emergency department 30 minutes after being rescued from a residential fire. Her airway is patent, and she is hemodynamically stable. Physical examination reveals deep partial-thickness and full-thickness burns involving her entire anterior trunk, her entire right arm, and her entire right leg. Her estimated weight is 80 kg80 \text{ kg}. Using the Parkland resuscitation formula (4 mL/kg/%TBSA4 \text{ mL/kg/} \% \text{TBSA}), what should be the target rate of intravenous lactated Ringer solution administration, in mL/hour\text{mL/hour}, for the first 8 hours following her injury?

Show answer & explanation

Answer: 900

Answer

900
The correct administration rate is 900 mL/hour900 \text{ mL/hour}. According to the Rule of Nines for adult patients, the anterior trunk constitutes 18%18\% TBSA, an entire arm is 9%9\%, and an entire leg is 18%18\%, totaling 45%45\% TBSA burned. Applying the given Parkland formula (4 mL×weight in kg×%TBSA4 \text{ mL} \times \text{weight in kg} \times \% \text{TBSA}), the total 24-hour fluid requirement is 4×80×45=14,400 mL4 \times 80 \times 45 = 14,400 \text{ mL}. Standard burn resuscitation guidelines dictate that 50%50\% of this total volume (7,200 mL7,200 \text{ mL}) must be administered over the first 8 hours following the injury. Dividing this initial volume by 8 hours yields an hourly rate of 900 mL/hour900 \text{ mL/hour}.

Step-by-Step Solution

1
Calculate the Total Body Surface Area (TBSA) affected by the burns.
Anterior trunk (18%) + entire right arm (9%) + entire right leg (18%) = 45% TBSA.
Accurate estimation of the burn area using the Rule of Nines is required to calculate fluid needs.
2
Calculate the total volume of fluid required for the first 24 hours.
4 mL×80 kg×45=14,400 mL4 \text{ mL} \times 80 \text{ kg} \times 45 = 14,400 \text{ mL}
The Parkland formula is used to determine the total 24-hour resuscitation volume requirement.
3
Determine the fluid volume to be administered during the first 8 hours.
14,400 mL/2=7,200 mL14,400 \text{ mL} / 2 = 7,200 \text{ mL}
Standard burn resuscitation guidelines dictate that half (50%) of the total 24-hour fluid volume must be given in the first 8 hours.
4
Calculate the hourly intravenous infusion rate.
7,200 mL/8 hours=900 mL/hour7,200 \text{ mL} / 8 \text{ hours} = 900 \text{ mL/hour}
The rate is needed to properly set the infusion pump for the initial phase of resuscitation.

Key Concept

Calculation of burn fluid resuscitation rates using the Rule of Nines and the Parkland formula.
Question 23Question →

A clinical study evaluates a novel prophylactic drug for episodic tension-type headaches among 200 adult participants over a 6-month period. Participants are equally divided into two groups. In the group receiving the standard placebo, 30 out of 100 participants experience a severe headache episode. In the group receiving the novel prophylactic drug, 10 out of 100 participants experience a severe headache episode. Based on these findings, what is the number needed to treat (NNT) to prevent one severe headache episode?

Show answer & explanation

Answer: 5

Answer

5
The Number Needed to Treat (NNT) is the number of patients who must receive a particular therapy for one additional patient to benefit. It is calculated as 1 divided by the Absolute Risk Reduction (ARR). In this study, the ARR is the difference between the control event rate (30%) and the experimental event rate (10%), which equals 20% (0.20). Therefore, the NNT is 10.20=5\frac{1}{0.20} = 5.

Step-by-Step Solution

1
Calculate the event rate in the control (placebo) group.
CER=30100=0.30CER = \frac{30}{100} = 0.30
This establishes the baseline risk of the outcome without the intervention.
2
Calculate the event rate in the experimental (drug) group.
EER=10100=0.10EER = \frac{10}{100} = 0.10
This establishes the risk of the outcome with the intervention.
3
Calculate the Absolute Risk Reduction (ARR).
ARR=CER−EER=0.30−0.10=0.20ARR = CER - EER = 0.30 - 0.10 = 0.20
ARR represents the absolute difference in risk between the two groups.
4
Calculate the Number Needed to Treat (NNT).
NNT=1ARR=10.20=5NNT = \frac{1}{ARR} = \frac{1}{0.20} = 5
NNT is the inverse of the ARR, representing the number of patients who need to receive the treatment to prevent one additional negative outcome.

Key Concept

The Number Needed to Treat (NNT) is calculated as the inverse of the Absolute Risk Reduction (NNT=1ARRNNT = \frac{1}{ARR}), representing the number of patients that must be treated to prevent one additional adverse outcome.
Question 24Question →

A randomized controlled trial is conducted to evaluate a new selective estrogen receptor modulator (SERM) for the prevention of breast cancer in high-risk postmenopausal women. The study enrolls 1,600 women, who are randomly assigned in a 1:1 ratio to receive either the new SERM or a placebo. The participants are followed for 5 years. During the follow-up period, 56 out of the 800 women receiving the new SERM develop deep vein thrombosis (DVT). In the placebo group, 16 out of the 800 women develop DVT.

Based on these study results, what is the number needed to harm (NNH) for DVT associated with this new SERM?

Show answer & explanation

Answer: 20

Answer

20
The number needed to harm (NNH) is an epidemiological measure that indicates how many patients need to be exposed to a risk factor (in this case, the new SERM) over a specific period to cause harm in one patient that would not otherwise have been harmed. It is calculated as the inverse of the Absolute Risk Increase (ARI). First, the incidence of the adverse event in the exposed group is 56/800=0.0756 / 800 = 0.07. The incidence in the unexposed (placebo) group is 16/800=0.0216 / 800 = 0.02. The ARI is the difference between these two incidences: 0.07−0.02=0.050.07 - 0.02 = 0.05. The NNH is calculated as 1/ARI1 / ARI, which is 1/0.05=201 / 0.05 = 20. Therefore, 20 patients must be treated with the new SERM for 5 years to result in one additional case of deep vein thrombosis compared to placebo.

Step-by-Step Solution

1
Determine the incidence of deep vein thrombosis in the experimental (SERM) group.
56 / 800 = 0.07
This establishes the risk of the adverse event when exposed to the new medication.
2
Determine the incidence of deep vein thrombosis in the control (placebo) group.
16 / 800 = 0.02
This establishes the baseline risk of the adverse event without the new medication.
3
Calculate the Absolute Risk Increase (ARI) by finding the difference in incidences.
0.07 - 0.02 = 0.05
ARI represents the excess risk of the adverse event attributable to the medication.
4
Calculate the Number Needed to Harm (NNH) by taking the reciprocal of the ARI.
1 / 0.05 = 20
NNH indicates the number of patients who need to be treated for one additional patient to experience an adverse event.

Key Concept

Number Needed to Harm (NNH)
Question 25Question →

Investigators at a regional cardiovascular center analyze data from a prospective study evaluating a new oral anticoagulant compared to standard therapy for stroke prevention. The study followed patients with nonvalvular atrial fibrillation over a two-year period. Among the 1,0001,000 patients receiving the new anticoagulant, 2020 experienced an ischemic stroke. Among the 1,0001,000 patients receiving standard therapy, 7070 experienced an ischemic stroke. Based on these findings, what is the number needed to treat with the new anticoagulant to prevent one additional ischemic stroke compared to standard therapy?

Show answer & explanation

Answer: 20

Answer

The number needed to treat is 20.
The Number Needed to Treat (NNT) represents the number of patients who need to receive the experimental therapy rather than the standard therapy to prevent one additional adverse event. It is calculated as the inverse of the Absolute Risk Reduction (ARR). The ARR is the difference between the control event rate (70/1000=0.0770/1000 = 0.07) and the experimental event rate (20/1000=0.0220/1000 = 0.02). This difference is 0.050.05. Therefore, the NNT is 10.05\frac{1}{0.05}, which equals 2020 patients.

Step-by-Step Solution

1
Calculate the control event rate (CER)
CER=701000=0.07\text{CER} = \frac{70}{1000} = 0.07
Establishing the baseline risk of the adverse event in the population receiving standard therapy.
2
Calculate the experimental event rate (EER)
EER=201000=0.02\text{EER} = \frac{20}{1000} = 0.02
Establishing the risk of the adverse event in the population receiving the new intervention.
3
Calculate the Absolute Risk Reduction (ARR)
ARR=0.07−0.02=0.05\text{ARR} = 0.07 - 0.02 = 0.05
Determining the absolute difference in event rates between the two groups.
4
Calculate the Number Needed to Treat (NNT)
NNT=10.05=20\text{NNT} = \frac{1}{0.05} = 20
NNT is the inverse of the ARR, representing the number of patients required to receive the new treatment to prevent one additional event.

Key Concept

Number Needed to Treat (NNT) and Absolute Risk Reduction (ARR)
Question 26Question →

Investigators are evaluating the efficacy of a newly developed long-acting monoclonal antibody for preventing severe respiratory syncytial virus (RSV) infections in high-risk premature infants. A total of 5,0005,000 infants are enrolled and randomized in a 1:1 ratio to receive either the monoclonal antibody or a placebo injection at the start of the RSV season. All participants are followed for 150150 days. At the end of the follow-up period, data analysis reveals that 5050 infants in the monoclonal antibody group and 150150 infants in the placebo group required hospitalization for severe RSV infection.

Based on these study results, what is the number needed to treat to prevent one RSV-related hospitalization?

Show answer & explanation

Answer: 25

Answer

25
The Number Needed to Treat (NNT) quantifies the number of patients who must receive a specific intervention to prevent one additional adverse event. It is calculated by first determining the event rates in both the control and intervention groups. Here, the event rate in the placebo (control) group is 150/2,500=0.06150 / 2,500 = 0.06. The event rate in the monoclonal antibody (intervention) group is 50/2,500=0.0250 / 2,500 = 0.02. The Absolute Risk Reduction (ARR) is the difference between these two rates (0.06−0.02=0.040.06 - 0.02 = 0.04). Finally, the NNT is the reciprocal of the ARR: 1/0.04=251 / 0.04 = 25. Thus, 25 infants need to receive the monoclonal antibody to prevent one hospitalization for severe RSV.

Step-by-Step Solution

1
Determine the number of patients in each study group.
Because 5,0005,000 infants were randomized in a 1:1 ratio, there are 2,5002,500 infants in the monoclonal antibody group and 2,5002,500 infants in the placebo group.
Accurate denominators are required to calculate the correct event rates for each study arm.
2
Calculate the event rate in the control group (ERcontrolER_{control}).
ERcontrol=1502500=0.06ER_{control} = \frac{150}{2500} = 0.06 (or 6%6\%).
The baseline risk of the outcome without the intervention must be established.
3
Calculate the event rate in the intervention group (ERinterventionER_{intervention}).
ERintervention=502500=0.02ER_{intervention} = \frac{50}{2500} = 0.02 (or 2%2\%).
The risk of the outcome with the intervention must be established to compare against the baseline.
4
Calculate the Absolute Risk Reduction (ARR).
ARR=ERcontrol−ERintervention=0.06−0.02=0.04ARR = ER_{control} - ER_{intervention} = 0.06 - 0.02 = 0.04.
ARR represents the absolute difference in risk between the two groups, which is required to calculate the NNT.
5
Calculate the Number Needed to Treat (NNT).
NNT=1ARR=10.04=25NNT = \frac{1}{ARR} = \frac{1}{0.04} = 25.
NNT is the inverse of the ARR, representing how many patients must be treated to prevent one additional adverse outcome.

Key Concept

The Number Needed to Treat (NNT) is calculated as the reciprocal of the Absolute Risk Reduction (ARR), where ARR is the difference in event rates between the control and intervention groups (NNT=1ARRNNT = \frac{1}{ARR}).
Question 27Question →

A group of researchers is investigating a new serological assay for a tick-borne illness. They recruit 1,0001,000 subjects from an endemic region. All subjects undergo both the new serological assay and the gold-standard polymerase chain reaction (PCR) test.

The PCR test confirms that 100100 subjects have the illness.
Among these 100100 infected subjects, 9090 have a positive result on the new serological assay.
Among the 900900 subjects who test negative for the illness by PCR, 810810 test negative on the new serological assay, while 9090 test positive.

A 3535-year-old man from this region undergoes the new serological assay, and the result is positive. Based on the study results, what is the percentage probability that this man actually has the tick-borne illness?

Show answer & explanation

Answer: 50

Answer

50
The question asks for the probability that a patient with a positive test actually has the disease, given the population parameters provided. This requires calculating the ratio of true positives to total positives. The true positives are the 90 infected subjects who tested positive. The total positive tests include these 90 true positives plus the 90 uninfected subjects who falsely tested positive (90 + 90 = 180). Therefore, the probability is 90 / 180 = 0.50, or 50%.

Step-by-Step Solution

1
Determine the number of True Positives (TP).
TP = 90
These are the individuals who actually have the disease (PCR positive) and returned a positive result on the new assay.
2
Determine the number of False Positives (FP).
FP = 90
These are the individuals who do not have the disease (PCR negative) but incorrectly returned a positive result on the new assay.
3
Calculate the probability that a patient with a positive test result actually has the disease.
50%
The calculation is TP divided by the total number of positive tests (TP + FP), which is 90 / (90 + 90) = 50%.

Key Concept

The probability that a patient with a positive test result actually has the disease is determined by calculating the True Positives divided by the Total Positives (True Positives + False Positives).
Question 28Question →

A pharmaceutical company conducts a 3-year, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a novel medication in preventing the progression to end-stage renal disease (ESRD) in patients with type 2 diabetes and chronic kidney disease. A total of 3,000 patients are enrolled and randomly assigned in a 1:1 ratio to receive either the novel medication or a placebo. All patients complete the 3-year follow-up period. The study results are summarized in the following table:

GroupDeveloped ESRDDid Not Develop ESRDTotal
Novel medication12013801500
Placebo18013201500

Based on the information provided, how many patients must be treated with the novel medication for 3 years to prevent one additional case of end-stage renal disease compared to placebo?

Show answer & explanation

Answer: 25

Answer

25 patients
The Number Needed to Treat (NNT) is defined as the number of patients who need to receive a specific intervention instead of the alternative to prevent one additional adverse outcome. It is calculated as the inverse of the Absolute Risk Reduction (ARR). First, calculate the risk of the event in the control group: 180/1500=0.12180 / 1500 = 0.12. Next, calculate the risk in the treatment group: 120/1500=0.08120 / 1500 = 0.08. The ARR is the difference between these two risks: 0.12−0.08=0.040.12 - 0.08 = 0.04. Finally, the NNT is 1/ARR1 / \text{ARR}, which equals 1/0.04=251 / 0.04 = 25. Therefore, 25 patients need to be treated with the novel medication for 3 years to prevent one additional case of ESRD.

Step-by-Step Solution

1
Calculate the Control Event Rate (CER)
CER = 180 / 1500 = 0.12
To determine the baseline risk of developing ESRD without the active medication.
2
Calculate the Experimental Event Rate (EER)
EER = 120 / 1500 = 0.08
To determine the risk of developing ESRD while taking the novel medication.
3
Calculate the Absolute Risk Reduction (ARR)
ARR = 0.12 - 0.08 = 0.04
To find the absolute difference in risk between the placebo and treatment groups.
4
Calculate the Number Needed to Treat (NNT)
NNT = 1 / 0.04 = 25
The NNT is the inverse of the Absolute Risk Reduction, indicating how many patients must be treated to prevent one adverse event.

Key Concept

The Number Needed to Treat (NNT) is calculated as the inverse of the Absolute Risk Reduction (ARR).
Question 29Question →

A clinical study is conducted to evaluate a novel rapid diagnostic test for a specific bacterial infection. The study enrolls 1,0001,000 participants. A gold standard culture method confirms that 100100 participants currently have the infection. The novel rapid test returns a positive result for 9090 of the infected participants. Additionally, the rapid test returns a positive result for 3030 participants who do not have the infection. All other participants tested negative. What is the positive predictive value of this novel rapid diagnostic test, expressed as a percentage?

Show answer & explanation

Answer: 75

Answer

75
The positive predictive value (PPV) is the probability that a patient actually has the disease given a positive test result. It is calculated by dividing the number of true positives (TP) by the total number of individuals who tested positive (TP + FP). In this study, 9090 infected participants tested positive (TP = 9090) and 3030 uninfected participants tested positive (FP = 3030). The total number of positive tests is 90+30=12090 + 30 = 120. Therefore, the PPV=90120=0.75PPV = \frac{90}{120} = 0.75, which is 75%75\%.

Step-by-Step Solution

1
Identify the true positive (TP) count.
TP = 90
These are the individuals who actually have the infection and correctly received a positive test result.
2
Identify the false positive (FP) count.
FP = 30
These are the individuals who do not have the infection but incorrectly received a positive test result.
3
Calculate the Positive Predictive Value (PPV).
PPV = 90 / (90 + 30) = 90 / 120 = 0.75
PPV measures the proportion of positive test results that are true positives.
4
Convert the resulting decimal to a percentage.
75%
The question asks for the answer to be expressed as a percentage.

Key Concept

Positive Predictive Value (PPV)
Question 30Question →

A gastroenterology research team is evaluating a novel non-invasive breath test for the detection of early-stage liver cirrhosis. The gold standard for confirming the diagnosis is a liver biopsy. The researchers conduct a study involving 800800 adult patients with chronic liver disease.

The results of the study are as follows:
- Liver biopsy confirms early-stage cirrhosis in 200200 patients.
- Among these 200200 patients, 180180 have a positive breath test.
- Among the 600600 patients without cirrhosis on biopsy, 6060 have a positive breath test.

What is the positive predictive value of the novel breath test in this study cohort? Provide your answer as a whole number percentage.

Show answer & explanation

Answer: 75

Answer

75
The positive predictive value (PPV) is calculated by dividing the number of true positive results by the total number of positive test results (true positives + false positives). In this study, there are 180 true positives and 60 false positives. Thus, the total number of positive tests is 240. The PPV is calculated as 180 / 240 = 0.75, which translates to 75%.

Step-by-Step Solution

1
Identify the number of true positives (TP).
TP = 180
These are the patients who actually have the disease (cirrhosis) and correctly tested positive.
2
Identify the number of false positives (FP).
FP = 60
These are the patients who do not have the disease but incorrectly tested positive.
3
Calculate the total number of positive test results.
Total Positive Tests = TP + FP = 180 + 60 = 240
The denominator for calculating positive predictive value is all positive test results.
4
Calculate the Positive Predictive Value (PPV).
PPV = (180 / 240) * 100 = 75%
PPV is the proportion of true positives out of all positive test results.

Key Concept

Positive predictive value (PPV) is the probability that a patient with a positive test result actually has the disease. It is calculated as True Positives / (True Positives + False Positives).
Estimated Time:1m 0s
Question 31Question →

A public health department conducts a 10-year prospective cohort study to evaluate the association between a diet high in ultra-processed foods and the development of metabolic syndrome. The study enrolls 10,000 healthy adults without pre-existing metabolic conditions. Participants are categorized into two groups based on detailed dietary questionnaires. Over the 10-year follow-up period, the occurrence of new metabolic syndrome diagnoses is recorded. The results are summarized in the table below:

Dietary PatternDeveloped Metabolic SyndromeDid Not Develop Metabolic SyndromeTotal
High ultra-processed food consumption4004,6005,000
Low ultra-processed food consumption1504,8505,000

Based on these study results, what percentage of metabolic syndrome cases among the participants with high consumption of ultra-processed foods can be attributed to their dietary pattern?

Show answer & explanation

Answer: 62.5

Answer

62.5
The question asks for the percentage of disease cases among the exposed population that can be specifically attributed to the exposure. This is the definition of the Attributable Risk Percent (ARP), also known as the etiologic fraction. It is calculated using the formula: ARP=Iexposed−IunexposedIexposed×100ARP = \frac{I_{exposed} - I_{unexposed}}{I_{exposed}} \times 100, or alternatively ARP=RR−1RR×100ARP = \frac{RR - 1}{RR} \times 100. Using the incidence data from the table: Iexposed=0.08I_{exposed} = 0.08 and Iunexposed=0.03I_{unexposed} = 0.03. Therefore, ARP=0.08−0.030.08×100=62.5%ARP = \frac{0.08 - 0.03}{0.08} \times 100 = 62.5\%.

Step-by-Step Solution

1
Calculate the incidence of metabolic syndrome in the exposed group (high ultra-processed diet).
4005,000=0.08\frac{400}{5,000} = 0.08
The incidence in the exposed group (IexposedI_{exposed}) is required to determine the baseline risk associated with the exposure.
2
Calculate the incidence of metabolic syndrome in the unexposed group (low ultra-processed diet).
1505,000=0.03\frac{150}{5,000} = 0.03
The incidence in the unexposed group (IunexposedI_{unexposed}) provides the baseline risk without the primary exposure.
3
Calculate the Attributable Risk (AR).
0.08−0.03=0.050.08 - 0.03 = 0.05
AR represents the excess absolute risk of the disease directly tied to the exposure.
4
Calculate the Attributable Risk Percent (ARP).
(0.050.08)×100=62.5%(\frac{0.05}{0.08}) \times 100 = 62.5\%
ARP represents the proportion of disease cases among the exposed that are specifically attributable to the exposure.

Key Concept

Attributable Risk Percent (ARP)
Question 32Question →

Researchers conduct a randomized controlled trial to evaluate the efficacy of a novel recombinant vaccine against respiratory syncytial virus (RSV) in older adults. A total of 16,000 healthy volunteers aged 65 years and older are enrolled and randomly assigned in a 1:1 ratio to receive either the vaccine or a placebo. Over a 24-month follow-up period, the investigators record the incidence of severe lower respiratory tract disease (LRTD) confirmed by laboratory testing. The results are summarized in the following table:

GroupTotal ParticipantsCases of Severe LRTD
Placebo8,000120
Vaccine8,00040

Based on these study results, what is the number needed to treat (NNT) to prevent one case of severe LRTD?

Show answer & explanation

Answer: 100

Answer

The number needed to treat (NNT) is 100 patients.
The number needed to treat (NNT) represents the number of patients who need to receive a specific intervention to prevent one additional adverse outcome. It is mathematically defined as the inverse of the absolute risk reduction (ARR). First, we determine the baseline risk in the placebo group: 120/8,000=0.015120 / 8,000 = 0.015. Next, we determine the risk in the vaccine group: 40/8,000=0.00540 / 8,000 = 0.005. The ARR is the difference between these two rates: 0.015−0.005=0.0100.015 - 0.005 = 0.010. Finally, the NNT is the inverse of the ARR: 1/0.010=1001 / 0.010 = 100. Therefore, 100 older adults must be vaccinated to prevent one case of severe LRTD.

Step-by-Step Solution

1
Calculate the incidence of severe LRTD in the unexposed (placebo) group.
Iplacebo=1208,000=0.015I_{\text{placebo}} = \frac{120}{8,000} = 0.015 (or 1.5%1.5\%).
This establishes the baseline risk of the outcome without the intervention.
2
Calculate the incidence of severe LRTD in the exposed (vaccine) group.
Ivaccine=408,000=0.005I_{\text{vaccine}} = \frac{40}{8,000} = 0.005 (or 0.5%0.5\%).
This establishes the risk of the outcome with the intervention.
3
Calculate the Absolute Risk Reduction (ARR).
ARR=0.015−0.005=0.010\text{ARR} = 0.015 - 0.005 = 0.010 (or 1.0%1.0\%).
ARR measures the absolute difference in risk between the placebo and vaccine groups.
4
Calculate the Number Needed to Treat (NNT).
NNT=1ARR=10.010=100\text{NNT} = \frac{1}{\text{ARR}} = \frac{1}{0.010} = 100.
NNT is defined as the inverse of the ARR and represents the number of individuals who must be treated to prevent one additional adverse outcome.

Key Concept

Number Needed to Treat (NNT) is calculated as the inverse of the Absolute Risk Reduction (ARR), representing the absolute difference in event rates between the control and experimental groups.
Question 33Question →

An industrial city's health department is planning an intervention to completely eliminate occupational exposure to a specific aerosolized solvent. Historical data show that 30% of the city's adult residents are exposed to this solvent at their workplaces. Extensive cohort studies have demonstrated that the relative risk of developing a severe demyelinating neuropathy in exposed residents compared to unexposed residents is 3.03.0. The baseline annual incidence of this neuropathy in the unexposed population is 55 cases per 1,0001,000 people.

Assuming the intervention successfully reduces exposure to zero with an immediate effect on risk, and the population size remains stable, how many incident cases of this neuropathy will be prevented per 100,000100,000 residents in the first year?

Show answer & explanation

Answer: 300

Answer

300
The number of cases prevented in the entire population by eliminating the exposure is determined by the Population Attributable Risk (PAR). PAR is most directly calculated by determining the Attributable Risk (AR) in the exposed group (15−5=1015 - 5 = 10 per 1,0001,000) and multiplying it by the prevalence of the exposure (30%30\%). This yields a PAR of 33 per 1,0001,000, which scales to 300300 cases per 100,000100,000 population.

Step-by-Step Solution

1
Calculate the incidence in the exposed population (IeI_e).
Ie=15I_e = 15 cases per 1,0001,000 people
The relative risk (RR) is 3.03.0 and the baseline incidence in the unexposed (IuI_u) is 55 per 1,0001,000. Therefore, Ie=RR×Iu=3.0×5=15I_e = RR \times I_u = 3.0 \times 5 = 15.
2
Calculate the Attributable Risk (AR).
AR=10AR = 10 cases per 1,0001,000 people
AR is the excess incidence among the exposed individuals compared to the unexposed. AR=Ie−Iu=15−5=10AR = I_e - I_u = 15 - 5 = 10.
3
Calculate the Population Attributable Risk (PAR).
PAR=3PAR = 3 cases per 1,0001,000 people
PAR represents the excess incidence in the total population that is attributable to the exposure. It is calculated by multiplying the AR by the prevalence of exposure (PP). PAR=AR×P=10×0.30=3PAR = AR \times P = 10 \times 0.30 = 3.
4
Scale the PAR to the requested population size (100,000100,000).
300300 cases prevented
The question asks for the number of prevented cases per 100,000100,000 people. Since the PAR is 33 per 1,0001,000, we multiply by 100100 to scale the denominator: 3×100=3003 \times 100 = 300.

Key Concept

Population Attributable Risk (PAR) represents the excess incidence of a disease in a total population that is attributable to a specific exposure, and it indicates the absolute number of cases that could be prevented if the exposure were completely eliminated.
Question 34Question →

Occupational health physicians are investigating the respiratory effects of prolonged exposure to a novel industrial solvent used in paint manufacturing. A longitudinal study follows employees at several facilities over a 10-year period. The study includes 1,5001,500 floor workers who directly handle the solvent and 4,5004,500 administrative staff at the same facilities who have no direct solvent exposure. Over the study duration, 120120 of the floor workers and 9090 of the administrative staff are newly diagnosed with adult-onset asthma. Based on these results, what percentage of the asthma cases among the floor workers is theoretically attributable to their solvent exposure?

Show answer & explanation

Answer: 75

Answer

75
The question asks for the percentage of asthma cases among the solvent-handling workers (the exposed group) that is attributable to their exposure. This specifically describes the Attributable Risk Percent (ARP) or Etiologic Fraction. First, calculate the incidence in the exposed group (IeI_e): 120120 cases / 1,5001,500 workers = 0.080.08 (or 8%8\%). Next, calculate the incidence in the unexposed group (IuI_u): 9090 cases / 4,5004,500 workers = 0.020.02 (or 2%2\%). The formula for ARP is Ie−IuIe×100\frac{I_e - I_u}{I_e} \times 100. Plugging in the values gives 0.08−0.020.08×100=0.060.08×100=75%\frac{0.08 - 0.02}{0.08} \times 100 = \frac{0.06}{0.08} \times 100 = 75\%. Therefore, 75%75\% of the asthma cases in the floor workers are theoretically caused by the solvent exposure.

Step-by-Step Solution

1
Calculate the incidence of asthma in the exposed group (floor workers).
Ie=1201500=0.08I_e = \frac{120}{1500} = 0.08 (or 8%8\%).
Incidence in the exposed (IeI_e) is required to determine baseline risk associated with the exposure.
2
Calculate the incidence of asthma in the unexposed group (administrative staff).
Iu=904500=0.02I_u = \frac{90}{4500} = 0.02 (or 2%2\%).
Incidence in the unexposed (IuI_u) represents the baseline risk of the disease in the absence of the specific exposure.
3
Calculate the Attributable Risk Percent (ARP).
ARP=0.08−0.020.08×100=0.060.08×100=75%ARP = \frac{0.08 - 0.02}{0.08} \times 100 = \frac{0.06}{0.08} \times 100 = 75\%.
The question asks for the percentage of disease 'among the floor workers' (exposed group) that is attributable to the exposure, which is the definition of ARP.

Key Concept

Attributable Risk Percent (ARP) measures the proportion of disease cases in an exposed population that is directly attributable to the exposure. It is calculated as Ie−IuIe×100\frac{I_e - I_u}{I_e} \times 100 or RR−1RR×100\frac{RR - 1}{RR} \times 100.
Question 35Question →

Public health researchers are analyzing data from a recent prospective cohort study investigating the adverse effects of a new oral synthetic retinoid used for severe nodular acne. The study followed 400400 patients taking the new retinoid and 400400 patients taking standard topical therapies for one year. During the study period, 5050 patients in the new retinoid group developed significantly elevated liver transaminases. In the standard therapy group, 1010 patients developed similar transaminase elevations. Based on these findings, what is the number needed to harm (NNH) for the new oral synthetic retinoid compared to standard therapy?

Show answer & explanation

Answer: 10

Answer

10
The Number Needed to Harm (NNH) represents the number of patients who must be exposed to a risk factor (or treatment) over a specific period to cause one additional adverse outcome. It is calculated as the inverse of the Absolute Risk Increase (ARI), which is also known as the Attributable Risk. First, the incidence of the adverse event in the exposed group is 50/400=12.5%50/400 = 12.5\%. Next, the incidence in the unexposed group is 10/400=2.5%10/400 = 2.5\%. The ARI is the difference between these two incidences: 12.5%−2.5%=10%12.5\% - 2.5\% = 10\% (or 0.100.10). The NNH is calculated as 1/ARI1 / \text{ARI}, which is 1/0.10=101 / 0.10 = 10. Therefore, 1010 patients need to be treated with the new retinoid instead of standard therapy to cause one additional case of elevated liver transaminases.

Step-by-Step Solution

1
Calculate the incidence of elevated transaminases in the exposed group (new oral retinoid).
50/400=0.12550 / 400 = 0.125 or 12.5%12.5\%
To determine the absolute risk of the adverse event in patients receiving the new drug.
2
Calculate the incidence of elevated transaminases in the unexposed group (standard therapy).
10/400=0.02510 / 400 = 0.025 or 2.5%2.5\%
To determine the baseline absolute risk of the adverse event in patients not receiving the new drug.
3
Calculate the Absolute Risk Increase (ARI).
0.125−0.025=0.100.125 - 0.025 = 0.10 or 10%10\%
ARI represents the excess risk of the adverse event attributable to the new drug.
4
Calculate the Number Needed to Harm (NNH).
1/0.10=101 / 0.10 = 10
NNH is the inverse of the ARI, representing the number of patients who need to be treated for one additional adverse event to occur.

Key Concept

Number Needed to Harm (NNH) is calculated as the inverse of the Absolute Risk Increase (ARI) between an exposed and an unexposed group.
Question 36Question →

Investigators are designing a clinical trial to evaluate a novel monoclonal antibody for the treatment of severe asthma. During the study design phase, they establish an acceptable probability of a Type I error (α\alpha) at 0.050.05. They also calculate that the probability of failing to reject the null hypothesis when it is actually false is 0.200.20. What is the statistical power of this study expressed as a percentage?

Show answer & explanation

Answer: 80

Answer

80
The statistical power of a study is defined as the probability of correctly rejecting the null hypothesis when it is indeed false. It is mathematically defined as 1−β1 - \beta, where β\beta is the probability of making a Type II error. In this scenario, the probability of failing to reject a false null hypothesis (Type II error) is 0.200.20. Therefore, the power is 1−0.20=0.801 - 0.20 = 0.80, which corresponds to 80%80\%.

Step-by-Step Solution

1
Identify the provided variables from the vignette.
The probability of a Type I error (α\alpha) is 0.050.05, and the probability of a Type II error (β\beta) is 0.200.20.
Recognizing the definitions of alpha and beta errors is necessary to select the correct formula for power.
2
Recall the formula for statistical power.
Power = 1−β1 - \beta
Statistical power is defined as the probability of correctly rejecting a false null hypothesis, which is the complement of the Type II error rate.
3
Calculate the power and convert it to a percentage.
Power = 1−0.20=0.801 - 0.20 = 0.80, which is 80%80\%.
The question specifically asks for the power expressed as a percentage.

Key Concept

Statistical power is the probability of correctly rejecting the null hypothesis when it is false. It is calculated as 1−β1 - \beta, where β\beta is the Type II error rate.
Question 37Question →

A prospective cohort study is conducted to evaluate the association between a severe sedentary lifestyle and the development of peripheral artery disease (PAD). The study enrolls 10,000 middle-aged adults without preexisting cardiovascular disease. At baseline, researchers identify that 2,500 participants meet the criteria for a severe sedentary lifestyle. Over a 10-year follow-up period, 250 of the participants with a severe sedentary lifestyle develop PAD. During the same period, 150 of the remaining participants develop PAD.

Based on these findings, what percentage of the overall PAD incidence in this study population is directly attributable to a severe sedentary lifestyle? (Provide your answer as a numerical percentage).

Show answer & explanation

Answer: 50

Answer

50
The correct response is 50. The question asks for the percentage of the overall disease burden attributable to the risk factor, which is the Population Attributable Risk Percent (PARP). PARP is calculated as Itotal−IunexposedItotal\frac{I_{\text{total}} - I_{\text{unexposed}}}{I_{\text{total}}}. The total incidence (ItotalI_{\text{total}}) is the total number of cases (250+150=400250 + 150 = 400) divided by the total population (10,00010,000), which equals 0.040.04. The unexposed incidence (IunexposedI_{\text{unexposed}}) is the number of cases in the unexposed group (150150) divided by the number of unexposed individuals (10,000−2,500=7,50010,000 - 2,500 = 7,500), which equals 0.020.02. Plugging these into the formula yields 0.04−0.020.04=0.020.04=0.50\frac{0.04 - 0.02}{0.04} = \frac{0.02}{0.04} = 0.50, or 50%.

Step-by-Step Solution

1
Determine the specific epidemiological metric requested by the question stem.
The metric required is Population Attributable Risk Percent (PARP).
The question asks for the percentage of the 'overall PAD incidence in this study population' that is attributable to the risk factor, rather than just the disease in the exposed individuals.
2
Calculate the incidence of the disease in the unexposed group (IunexposedI_{\text{unexposed}}).
Iunexposed=1507,500=0.02I_{\text{unexposed}} = \frac{150}{7,500} = 0.02 (2%).
This establishes the baseline risk of developing PAD without the severe sedentary lifestyle, which is needed to find the excess risk in the population.
3
Calculate the incidence of the disease in the total population (ItotalI_{\text{total}}).
Itotal=40010,000=0.04I_{\text{total}} = \frac{400}{10,000} = 0.04 (4%).
This is the denominator for the PARP formula, representing the overall burden of disease in the cohort.
4
Calculate the Population Attributable Risk Percent (PARP).
PARP=0.04−0.020.04×100=50%PARP = \frac{0.04 - 0.02}{0.04} \times 100 = 50\%.
PARP is defined as (Itotal−Iunexposed)/Itotal(I_{\text{total}} - I_{\text{unexposed}}) / I_{\text{total}}, yielding the proportion of total disease burden directly linked to the exposure.

Key Concept

Population Attributable Risk Percent (PARP) measures the proportion of the incidence of a disease in the total population (exposed and unexposed combined) that is due to the exposure.
Question 38Question →

Emergency medicine researchers are investigating a novel rapid point-of-care ultrasound algorithm for deep vein thrombosis (DVT). In their study cohort of symptomatic patients with a high pre-test probability, the true prevalence of DVT is 40%40\%.

During the initial evaluation using standard diagnostic criteria, the algorithm yields a sensitivity of 85%85\% and a specificity of 85%85\%.

To minimize missed diagnoses, the researchers broaden the criteria for a positive scan. Statistical analysis of the cohort reveals that this protocol change reduces the absolute number of false-negative results by exactly 50%50\% compared to the standard criteria. However, this adjustment simultaneously causes the absolute number of false-positive results to increase by exactly 100%100\% compared to the standard criteria.

Calculate the negative predictive value (NPV) of the ultrasound algorithm using the broadened criteria. Express your answer as a percentage rounded to the nearest whole number.

Show answer & explanation

Answer: 93

Answer

93
To calculate the new NPV, one must first determine the absolute number of patients in each category of a 2x2 contingency table. Assuming a cohort of 1,0001,000 patients with a 40%40\% prevalence, 400400 patients have DVT and 600600 do not. At the baseline 85%85\% sensitivity and specificity, there are 340340 true positives, 6060 false negatives (400−340400 - 340), 510510 true negatives, and 9090 false positives (600−510600 - 510). The broadened criteria reduce the false negatives by 50%50\% (from 6060 to 3030) and increase the false positives by 100%100\% (from 9090 to 180180). Because the total number of patients without DVT is fixed at 600600, an increase in false positives to 180180 means the true negatives must decrease to 420420 (600−180600 - 180). The new Negative Predictive Value is the number of true negatives divided by the total number of negative test results: NPV=TNTN+FN=420420+30=420450≈0.9333\text{NPV} = \frac{\text{TN}}{\text{TN} + \text{FN}} = \frac{420}{420 + 30} = \frac{420}{450} \approx 0.9333. Expressed as a percentage and rounded to the nearest whole number, this is 93%93\%.

Step-by-Step Solution

1
Determine the number of patients with and without the disease in a hypothetical cohort.
In a 1,0001,000 patient cohort with 40%40\% prevalence: 400400 have DVT (disease positive) and 600600 do not have DVT (disease negative).
Creating a 2x2 contingency table with absolute numbers simplifies predictive value calculations.
2
Calculate the baseline number of false negatives (FN) and false positives (FP).
Baseline FN = 400−(0.85×400)=60400 - (0.85 \times 400) = 60. Baseline FP = 600−(0.85×600)=90600 - (0.85 \times 600) = 90.
The protocol modifications are given as percentage changes relative to the baseline absolute error numbers.
3
Apply the protocol changes to find the new absolute numbers of FN and FP.
New FN = 60−(0.50×60)=3060 - (0.50 \times 60) = 30. New FP = 90+(1.00×90)=18090 + (1.00 \times 90) = 180.
Broadening criteria decreases missed cases (FN) by 50%50\% but doubles the false alarms (FP).
4
Calculate the new number of true negatives (TN).
New TN = (Total Disease Negative) - (New FP) = 600−180=420600 - 180 = 420.
The denominator for NPV requires the TN, which must be derived from the fixed disease-negative population.
5
Calculate the Negative Predictive Value (NPV).
NPV=TNTN+FN=420420+30=420450≈0.9333\text{NPV} = \frac{\text{TN}}{\text{TN} + \text{FN}} = \frac{420}{420 + 30} = \frac{420}{450} \approx 0.9333 (93.33%93.33\%).
NPV represents the probability that a patient with a negative test result truly does not have the disease.

Key Concept

Recalculating predictive values after a diagnostic threshold shift by tracking absolute changes in a 2x2 contingency table.
Question 39Question →

Researchers are designing a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a novel anti-obesity medication. Initially, the trial is designed to detect a mean weight loss difference of 5.0 kg5.0\text{ kg} between the treatment and placebo groups. Based on pilot data, the expected standard deviation of weight loss is estimated at 10.0 kg10.0\text{ kg} in both groups. Using a two-sided α\alpha of 0.050.05 and 80%80\% power, the investigators calculate a required sample size of 6464 participants per group.

Prior to patient enrollment, a newly published meta-analysis indicates a larger population variability, suggesting the true standard deviation is 15.0 kg15.0\text{ kg}. In light of this, the investigators revise their protocol to ensure even more conservative clinical benefits can be detected, setting the new minimum detectable mean difference at 3.0 kg3.0\text{ kg}.

Assuming the type I error rate (α\alpha) and statistical power remain unchanged, what is the newly calculated required sample size per group?

Show answer & explanation

Answer: 400

Answer

The newly calculated required sample size is 400 participants per group.
The required sample size for a continuous outcome in a superiority trial is calculated using the formula N=2(Zα/2+Zβ)2σ2Δ2N = \frac{2(Z_{\alpha/2} + Z_{\beta})^2 \sigma^2}{\Delta^2}, where σ\sigma is the standard deviation and Δ\Delta is the minimum detectable difference. From this formula, it is clear that the sample size is directly proportional to the variance (σ2\sigma^2) and inversely proportional to the squared difference (Δ2\Delta^2).

When the standard deviation increases from 10.010.0 to 15.015.0 (a factor of 1.51.5 or 3/23/2), the variance increases by a factor of (3/2)2=9/4(3/2)^2 = 9/4.
When the minimum detectable difference decreases from 5.05.0 to 3.03.0, the required sample size increases by the inverse square factor, which is (5/3)2=25/9(5/3)^2 = 25/9.

Multiplying the original sample size of 6464 by these two adjustment factors yields: 64×94×25964 \times \frac{9}{4} \times \frac{25}{9}. The 99 s cancel out, leaving 64×254=16×25=40064 \times \frac{25}{4} = 16 \times 25 = 400.

Step-by-Step Solution

1
Identify the mathematical relationship between sample size, variance, and effect size.
Sample size N∝σ2Δ2N \propto \frac{\sigma^2}{\Delta^2}
To determine how changes in standard deviation (σ\sigma) and minimum detectable difference (Δ\Delta) mathematically scale the required sample size.
2
Calculate the multiplier for the change in variance.
Variance Multiplier = (15.010.0)2=1.52=94(\frac{15.0}{10.0})^2 = 1.5^2 = \frac{9}{4}
Sample size is directly proportional to the variance (σ2\sigma^2), which is the square of the standard deviation.
3
Calculate the multiplier for the change in the minimum detectable difference.
Difference Multiplier = (5.03.0)2=259(\frac{5.0}{3.0})^2 = \frac{25}{9}
Sample size is inversely proportional to the square of the effect size difference (Δ2\Delta^2).
4
Calculate the new sample size by applying both multipliers to the original sample size.
New N=64×94×259=64×254=16×25=400N = 64 \times \frac{9}{4} \times \frac{25}{9} = 64 \times \frac{25}{4} = 16 \times 25 = 400
To accurately find the final required sample size after adjusting for both new parameters without needing complex Z-score recalculations.

Key Concept

In clinical trial design, the required sample size for a continuous outcome is directly proportional to the variance (the square of the standard deviation) and inversely proportional to the square of the minimum detectable difference.
Question 40Question →

A prospective cohort study is conducted to evaluate the association between a diet high in ultra-processed foods and the development of colorectal cancer. The investigators enroll 50,000 healthy adults aged 45 to 60 years. At baseline, participants complete detailed dietary questionnaires and are categorized based on their dietary patterns. The high ultra-processed food (UPF) consumption group includes 10,000 participants, while the low UPF consumption group includes 40,000 participants.

All participants are followed for 15 years. During the follow-up period, 400 incident cases of colorectal cancer are diagnosed among the participants in the high UPF group. In the low UPF group, 400 incident cases of colorectal cancer are diagnosed.

Based on the study results, what percentage of the colorectal cancer cases among the participants with high ultra-processed food consumption is attributable to their high UPF diet?

Show answer & explanation

Answer: 75

Answer

The attributable risk percent is 75%.
The question asks for the percentage of disease among the exposed group (high UPF consumption) that is attributable to the exposure. This is the definition of Attributable Risk Percent (ARP), also known as the etiologic fraction in the exposed. It is calculated by determining the excess risk in the exposed group (Attributable Risk, or Ie−IuI_e - I_u) and dividing it by the total risk in the exposed group (IeI_e). First, calculate the incidence in the exposed (IeI_e): 400/10,000=0.04400 / 10,000 = 0.04. Next, calculate the incidence in the unexposed (IuI_u): 400/40,000=0.01400 / 40,000 = 0.01. The excess risk (AR) is 0.04−0.01=0.030.04 - 0.01 = 0.03. Finally, divide the excess risk by the total risk in the exposed: 0.03/0.04=0.750.03 / 0.04 = 0.75, or 75%75\%.

Step-by-Step Solution

1
Calculate the incidence rate in the exposed group (IeI_e).
Ie=400/10,000=0.04I_e = 400 / 10,000 = 0.04 (4%4\%)
This establishes the baseline absolute risk of developing the disease for those with the exposure.
2
Calculate the incidence rate in the unexposed group (IuI_u).
Iu=400/40,000=0.01I_u = 400 / 40,000 = 0.01 (1%1\%)
This establishes the background risk of the disease that occurs regardless of the exposure.
3
Calculate the Attributable Risk Percent (ARP) in the exposed.
ARP=0.04−0.010.04×100=75%ARP = \frac{0.04 - 0.01}{0.04} \times 100 = 75\%
ARP quantifies the percentage of cases in the exposed population that can be attributed directly to the exposure.

Key Concept

Attributable Risk Percent (ARP)
PreviousPage 2 / 8Next
All practice questions — USMLE Step 2 CK | Examkin